Becton, Dickinson and Company (VIE:BDX)
Austria
· Delayed Price · Currency is EUR 165.65
+0.75 (0.45%)
At close: Dec 4, 2025
Revenue Breakdown
Fiscal year is October - September.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2012 - 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | 2012 - 2020 |
| Medication Delivery Solutions Revenue | 4.58B |
Log In |
Log In |
Log In | Upgrade
|
| Medication Management Solutions Revenue | 3.47B |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Systems Revenue | 2.32B |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Patient Monitoring Revenue | 1.08B |
Log In |
Log In |
Log In | Upgrade
|
| Specimen Management Revenue | 1.87B |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostic Solusions Revenue | 1.84B |
Log In |
Log In |
Log In | Upgrade
|
| Integrated Diagnostic Solutions Revenue | 3.71B |
Log In |
Log In |
Log In | Upgrade
|
| Biosciences Revenue | 1.46B |
Log In |
Log In |
Log In | Upgrade
|
| Surgery Revenue | 1.57B |
Log In |
Log In |
Log In | Upgrade
|
| Peripheral Intervention Revenue | 2.00B |
Log In |
Log In |
Log In | Upgrade
|
| Urology and Critical Care Revenue | 1.65B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | -3.71B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 21.84B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is October - September.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2012 - 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | 2012 - 2020 |
| United States Revenue | 12.79B |
Log In |
Log In |
Log In | Upgrade
|
| International Revenue | 9.05B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | 1.00M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 21.84B |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown 2
Fiscal year is October - September.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2012 - 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | 2012 - 2020 |
| Medical Revenue | 11.46B |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Revenue | 5.17B |
Log In |
Log In |
Log In | Upgrade
|
| Interventional Revenue | 5.22B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 21.84B |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is October - September.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2012 - 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | 2012 - 2020 |
| Medical Segment Operating Income | 4.14B |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Segment Operating Income | 1.64B |
Log In |
Log In |
Log In | Upgrade
|
| Interventional Segment Operating Income | 2.25B |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Other) | -5.46B |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 2.58B |
Log In |
Log In |
Log In | Upgrade
|
EBIT 2
Fiscal year is October - September.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2012 - 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | 2012 - 2020 |
| Medical Segment Operating Income (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Segment Operating Income (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
| Interventional Segment Operating Income (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 2.58B |
Log In |
Log In |
Log In | Upgrade
|